Articles published by Neuropathix, Inc.
Neuropathix, Inc. Highlights Positive Preclinical Study Results on Lead Drug Candidate KLS-13019
April 13, 2022
From Neuropathix, Inc.
Via AccessWire
Tickers
NPTX
Neuropathix, Inc. CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding
April 06, 2022
From Neuropathix, Inc.
Via AccessWire
Tickers
NPTX
Neuropathix, Inc. Welcomes Daniele Piomelli, PhD, MD to the Company’s Scientific Advisory Board
January 25, 2022
From Neuropathix, Inc.
Via AccessWire
Tickers
NPTX
Neuropathix, Inc. Receives Patent Grant from India for Its Novel Anti-Inflammatory Compounds
January 18, 2022
From Neuropathix, Inc.
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
NPTX
Neuropathix, Inc. Chooses Purisys for Process Optimization and Scale Up of Its Lead Drug Candidate KLS-13019
November 17, 2021
From Neuropathix, Inc.
Via AccessWire
Topics
Intellectual Property
Tickers
NPTX
From Neuropathix, Inc.
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
NPTX
Neuropathix, Inc. Appoints Michael Ropacki, PhD to the Company's Scientific Advisory Board
August 12, 2021
From Neuropathix, Inc.
Via AccessWire
Topics
Intellectual Property
Tickers
NPTX
From Neuropathix, Inc.
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
NPTX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free